

**AMENDMENT OF THE CLAIMS:**

1. (Original) A medicament dispenser device for use in the delivery of a multi-component combination medicament product, the device comprising

a first medicament container containing plural co-formulation compatible medicament components;

first release means for releasing the contents of the first medicament container for delivery thereof;

at least one further medicament container, each containing at least one co-formulation incompatible medicament component; and

at least one further release means for releasing the contents of each at least one further medicament container for delivery thereof,

wherein the at least one co-formulation incompatible medicament component is kept separate from the plural co-formulation compatible components until the point of release thereof for delivery in combination.

2. (Original) A medicament dispenser device according to claim 1, wherein the dispenser device comprises a first medicament container containing two co-formulation compatible medicament components and one further medicament container containing one co-formulation incompatible medicament component.

3. (Original) A medicament dispenser device according to claim 1, wherein the dispenser device comprises a first medicament container containing two co-formulation compatible medicament components and one further medicament container containing two co-formulation incompatible medicament components.

4. (Original) A medicament dispenser device according to claim 1, wherein the dispenser device comprises a first medicament container containing two co-formulation compatible medicament components a second medicament container

containing one co-formulation incompatible medicament component and a third medicament container containing one co-formulation incompatible medicament component.

5. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 4~~, wherein the first medicament container and the at least one further medicament container are suitable for use with a medicament dispenser selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), a unit dose dry powder inhaler (UDPI), a metered dose inhaler (MDI) and a liquid spray inhaler (LSI).

6. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 5~~, wherein the first and at least one further medicament container are of a similar type.

7. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 5~~, wherein the first and at least one further medicament container are of a different type.

8. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 7~~, wherein the first release means and the at least one further release means are coupled together

9. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 8~~, wherein the device further comprises a mixing chamber including a first inlet for receiving the released contents of the first medicament container; a second inlet for receiving the released contents of the at least one further medicament container; and an outlet for delivery of combination medicament product therefrom.

10. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 9~~, wherein the plural co-formulation compatible medicament components and the at least one co-formulation incompatible medicament component

are selected from the group consisting of anti-inflammatory agents, anticholinergic agents, other  $\beta_2$ -adrenoreceptor agonists, anti-infective agents and antihistamines.

11. (Original) A medicament dispenser device according to claim 10, wherein said anti-inflammatory agents are selected from the group consisting of corticosteroids and NSAIDs.

12. (Original) A medicament dispenser device according to claim 11, wherein said corticosteroids are selected from the group consisting of methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate,  $6\alpha,9\alpha$ -difluoro- $17\alpha$ -[(2-furanylcarbonyl)oxy]- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-fluoromethyl ester,  $6\alpha,9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo- $17\alpha$ -propionyloxy-androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-(2-oxo-tetrahydrofuran-3S-yl) ester, beclomethasone esters, budesonide, flunisolide, mometasone esters, triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR-106541 and ST-126.

13. (Original) A medicament dispenser device according to claim 12, wherein said corticosteroids are selected from the group consisting of fluticasone propionate,  $6\alpha,9\alpha$ -difluoro- $11\beta$ -hydroxy- $16\alpha$ -methyl- $17\alpha$ -[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-fluoromethyl ester and  $6\alpha,9\alpha$ -difluoro- $17\alpha$ -[(2-furanylcarbonyl)oxy]- $11\beta$ -hydroxy- $16\alpha$ -methyl-3-oxo-androsta-1,4-diene- $17\beta$ -carbothioic acid *S*-fluoromethyl ester.

14. (Currently amended) A medicament dispenser device according to claim 11 ~~any of claims 11 to 13~~, wherein said NSAIDs are selected from the group consisting of sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors, leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists, adenosine receptor agonists or antagonists, cytokine antagonists and inhibitors of cytokine synthesis.

15. (Original) A medicament dispenser device according to claim 14, wherein said phosphodiesterase (PDE) inhibitors are selected from the group consisting of theophylline, PDE4 inhibitors and mixed PDE3/PDE4 inhibitors.

16. (Original) A medicament dispenser device according to claim 10, wherein said other  $\beta_2$ -adrenoreceptor agonists are selected from the group consisting of salmeterol, salbutamol, formoterol, fenoterol, terbutaline and any salts or solvates thereof.

17. (Original) A medicament dispenser device according to claim 10, wherein said anticholinergic agents are selected from the group consisting of  $M_1$ ,  $M_2$ ,  $M_1/M_2$  and  $M_3$  receptor antagonists.

18. (Original) A medicament dispenser device according to claim 17, wherein said anticholinergic agents are selected from the group consisting of ipratropium, oxitropium, tiotropium and any salts or solvates thereof.

19. (Currently amended) A medicament dispenser device according to claim 1 ~~any of claims 1 to 18~~, wherein the plural co-formulation compatible medicament components comprise a  $\beta_2$ -adrenoreceptor agonist and a corticosteroid; and the at least one further co-formulation incompatible medicament component is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

20. (Original) A medicament dispenser device according to claim 19, wherein the  $\beta_2$ -adrenoreceptor agonists is selected from the group consisting of salbutamol, salmeterol, formoterol and any salts and solvates thereof; and the corticosteroid is selected from the group consisting of beclomethasone ester, a fluticasone ester, budesonide and any salts of solvates thereof.

21. (Original) A medicament dispenser device according to claim 20, wherein the plural co-formulation compatible medicament components comprise fluticasone propionate and salmeterol xinafoate; and the co-formulation incompatible component

is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

22. (Original) A medicament dispenser device according to claim 20, wherein the plural co-formulation compatible medicament components comprise budesonide and formoterol fumarate; and the co-formulation incompatible component is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

23. (Currently amended) A medicament pack for use with the medicament dispenser device according to claim 1 ~~any of claims 1 to 22~~, the pack comprising

a first medicament container containing plural co-formulation compatible medicament components; and

at least one further medicament container, each at least one further medicament container containing at least one co-formulation incompatible medicament component; and

wherein the at least one co-formulation incompatible medicament component is kept separate from the plural co-formulation compatible components.

24. (Original) A medicament pack according to claim 23, wherein the plural co-formulation compatible medicament components and the at least one co-formulation incompatible medicament component are selected from the group consisting of anti-inflammatory agents, anticholinergic agents, other  $\beta_2$ -adrenoreceptor agonists, anti-infective agents and antihistamines.

25. (Original) A medicament pack according to claim 24, wherein said anti-inflammatory agents are selected from the group consisting of corticosteroids and NSAIDs.

26. (Original) A medicament pack according to claim 25, wherein said corticosteroids are selected from the group consisting of methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 $\alpha$ ,9 $\alpha$ -difluoro-17 $\alpha$ -[(2-furanylcarbonyl)oxy]-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester, 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -propionyloxy- androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-(2-oxo-tetrahydrofuran-3S-yl) ester, beclomethasone esters, budesonide, flunisolide, mometasone esters, triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR-106541 and ST-126.

27. (Original) A medicament pack according to claim 26, wherein said corticosteroids are selected from the group consisting of fluticasone propionate, 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-17 $\alpha$ -[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester and 6 $\alpha$ ,9 $\alpha$ -difluoro-17 $\alpha$ -[(2-furanylcarbonyl)oxy]-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -carbothioic acid *S*-fluoromethyl ester.

28. (Currently amended) A medicament pack according to claim 25~~any of claims 25 to 27~~, wherein said NSAIDs are selected from the group consisting of sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors, leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists, adenosine receptor agonists or antagonists, cytokine antagonists and inhibitors of cytokine synthesis.

29. (Original) A medicament pack according to claim 28, wherein said phosphodiesterase (PDE) inhibitors are selected from the group consisting of theophylline, PDE4 inhibitors and mixed PDE3/PDE4 inhibitors.

30. (Original) A medicament pack according to claim 24, wherein said other  $\beta_2$ -adrenoreceptor agonists are selected from the group consisting of salmeterol, salbutamol, formoterol, fenoterol, terbutaline and any salts or solvates thereof.

31. (Original) A medicament pack according to claim 24, wherein said anticholinergic agents are selected from the group consisting of M<sub>1</sub>, M<sub>2</sub>, M<sub>1</sub>/M<sub>2</sub> and M<sub>3</sub> receptor antagonists.

32. (Original) A medicament pack according to claim 31, wherein said anticholinergic agents are selected from the group consisting of ipratropium, oxitropium, tiotropium and any salts or solvates thereof.

33. (Currently amended) A medicament pack according to claim 23~~any of claims 23 to 32~~, wherein the plural co-formulation compatible medicament components comprise a  $\beta_2$ -adrenoreceptor agonist and a corticosteroid; and the at least one further co-formulation incompatible medicament component is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

34. (Original) A medicament dispenser device according to claim 33, wherein the  $\beta_2$ -adrenoreceptor agonist is selected from the group consisting of salbutamol, salmeterol, formoterol and any salts and solvates thereof; and the corticosteroid is selected from the group consisting of beclomethasone ester, a fluticasone ester, budesonide and any salts of solvates thereof.

35. (Original) A medicament dispenser device according to claim 34, wherein the plural co-formulation compatible medicament components comprise fluticasone propionate and salmeterol xinafoate; and the co-formulation incompatible component is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

36. (Original) A medicament dispenser device according to claim 34, wherein the plural co-formulation compatible medicament components comprise budesonide and formoterol fumarate; and the co-formulation incompatible component is selected from the group consisting of a PDE-4 inhibitor, an anti-cholinergic, and any mixtures thereof.

37. (Currently amended) Refill medicament pack in kit of parts form for use with the medicament dispenser device according to claim 1 ~~any of claims 1 to 22~~, the refill pack comprising

as a first part of said kit, a first medicament container containing plural co-formulation compatible medicament components; and

as a further part of the kit, at least one further medicament container, each at least one further medicament container containing at least one co-formulation incompatible medicament component; and

wherein the at least one co-formulation incompatible medicament component is kept separate from the plural co-formulation compatible components.